Targeting KCa3.1 may therefore provide a novel and effective approach for the treatment of IPF and there is the potential for the rapid translation of KCa3.1-directed therapy to the clinic. The gene discussed is KCNN4; the disease is idiopathic pulmonary fibrosis.